Clinical trial · no report yet · Phase 2
NCT01824875
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
- NCT01824875 ↗
- Completed
- ECOG-ACRIN Cancer Research Group
- 11 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| X threads | 4 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma
- Interventions
- temozolomide; capecitabine
- Arms
- Arm A (temozolomide) · Experimental
- Arm B (temozolomide and capecitabine) · Experimental
- Enrollment
- 144
- Primary outcomes
- Progression-free Survival
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Aug 8, 2013
- Primary completion
- May 26, 2021
- Results posted
- Yes
- Registry record
- NCT01824875 · updated Sep 29, 2026
Publications
linked from the registry- Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB 3rd. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023 Mar 1;41(7):1359-1369. doi: 10.1200/JCO.22.01013. Epub 2022 Oct 19. PubMed 36260828